Document is current
Any future updates will be listed below
-
Authors
Cioe, Patricia A. https://orcid.org/0000-0003-3599-7819
Schnoll, Robert
Hoeppner, Bettina B.
Gross, Robert
Hitsman, Brian L.
Leone, Frank T.
Ashare, Rebecca
Vilardaga, Roger
Tashima, Karen
Pinkston, Megan
Kahler, Christopher W.
-
Funding
Funding for this research was provided by:
National Institutes of Health (5R21CA243906)
National Cancer Institute (R01 CA243914, R21CA243911)
- License Information
-
More Information
Article History
Accepted: 27 October 2022
First Online: 11 November 2022
Declarations
:
: Drs. Cioe, Hoeppner, Hitsman, Pinkston, Tashima, and Kahler have no relevant financial or non-financial interests to disclose. Dr. Schnoll received medication and placebo free of charge from Pfizer for clinical trials and has provided consultation to Pfizer, GlaxoSmithKline, and Curaleaf. Dr. Ashare received an investigator-initiated grant from Novo Nordisk, Inc for a study unrelated to the current project. Dr. Vilardaga is the principal investigator in an industry trial study funded by Happify Inc. Dr. Gross serves on a DSMB for a Pfizer medication unrelated to smoking or HIV.
: Approval was obtained by Institutional Review Boards at Brown University and the University of Pennsylvania.
: Informed consent was obtained from all individual participants included in the study.
: Not applicable.
Free to read: This content has been made available to all.
